• About us
• Contact

Advertisement

Document › Details

bioMérieux S.A.. (2/27/19). "Press Release: bioMérieux – 2018 Financial Results".

	Organisation	bioMérieux S.A. (Euronext: BIM)
	Group	Mérieux (Group)
	Product	molecular diagnostics
	Person	Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Organic sales growth of 9.9% for full-year 2018:
>> €2,421 million in sales
>> Up 5.8% as reported
>> Solid fourth-quarter performance, with organic growth of more than 10%

> Improvement in contributive operating income before non-recurring items, which came to €361 million or close to 15% of sales, despite unfavorable currency effect

> 2019 financial targets:
>> Organic growth in sales of between 7.0% and 8.5%, at constant exchange rates and scope of consolidation
>> Contributive operating income before non-recurring items of between €385 million and €400 million, at current exchange rates


Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In 2018, bioMérieux recorded very satisfactory results and stepped up the deployment of its immunoassay strategy, with Astute and Hybiome transactions. In 2019, bioMérieux intends to maintain its sales dynamics and to improve its operational and financial performance, for the benefit of clients and patients, true to its continued commitment to serve public health."

Download [ https://www.biomerieux.com/sites/corporate/files/news-event-press-release/biomerieux_pr_2018_results.pdf ]

Record changed: 2023-06-05

Advertisement

More documents for Mérieux (Group)

• [1] bioMérieux S.A.. (10/19/23). "Press Release: bioMérieux Makes Strategic Investment in Oxford Nanopore". Oxford & Marcy-l’Etoile....
• [2] bioMérieux S.A.. (4/14/23). "Press Release: Oxford Nanopore and bioMérieux to Enter into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics". Oxford & Marcy-l’Etoile....
• [3] InDevR, Inc.. (1/17/23). "Press Release: InDevR Raises $9 Million in Series B Financing and Partners with bioMérieux". Boulder, CO....
• [4] Weezion SAS. (6/1/22). "Press Release: Weezion, a French MedTech Start-up, Announces Capital Investment from bioMérieux". Lyon....
• [5] bioMérieux S.A.. (3/18/22). "Press Release: bioMérieux Receives FDA 510(k) Clearance for Its VITEK MS PRIME New MALDI-TOF Mass Spectrometry Identification System". Marcy l’Étoile....
• [6] bioMérieux S.A.. (6/6/19). "Press Release: bioMérieux Increases Its Holding in Hybiome from 54% to 67%". Marcy l’Étoile....
• [7] bioMérieux S.A.. (4/24/19). "Press Release: bioMérieux – First-Quarter 2019 Business Review". Marcy l’Étoile....
• [8] bioMérieux S.A.. (4/15/19). "Press Release: “Global-PPS”, a Survey of Antibiotic Use and Bacterial Resistance in Hospitals Worldwide, Tops the 200,000 Patients". Marcy l’Étoile & Antwerp....
• [9] bioMérieux S.A.. (4/1/19). "Press Release: University of Antwerp, bioMérieux, and Wellcome Trust to Coordinate VALUE-Dx, a European Public-Private Partnership to Fight Antimicrobial Resistance through Diagnostics". Antwerp, London & Marcy l’Eoile....
• [10] bioMérieux S.A.. (3/19/19). "Press Release: Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury". Deerfield, IL & Marcy l’Etoile....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.